Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $800 million versus the consensus estimate of $1.67 million.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.